Samsara Therapeutics, Inc. is biopharmaceutical company aiming to discover first-in-class therapeutics that treat rare genetic and neurodegenerative disease, and extend healthy lifespan. Samsara's platform is the largest ever pipeline for the identification, chemical optimization, and in vivo validation of compounds that enhance autophagy. Samsara Therapeutics is a global biotech company with operations in Oxford and Boston and significant academic collaborations in Paris and Graz
Location: United Kingdom, England, Oxford
Employees: 11-50
Total raised: $3.2M
Founded date: 2018
Investors 4
| Date | Name | Website |
| - | Apollo Ven... | apollo.vc |
| - | Longevityt... | longevityt... |
| - | Healthspan... | healthspan... |
| - | Korify Cap... | korifycapi... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 21.12.2019 | Seed | $3.2M | - |
Mentions in press and media 1
| Date | Title | Description |
| 27.04.2023 | Samsara Therapeutics unveils promising autophagy drug candidate, offering new hope for people with Parkinson's and motor neurone disease | BOSTON (PRWEB) April 27, 2023 The research presented today shows that SAM001 boosts autophagy and reduces damage to brain cells taken from people with Parkinson’s Disease and Amyotrophic Lateral Sclerosis (ALS)1. It does this by targeting T... |